当前位置： SCI文献检索 > INTERNATIONAL JOURNAL OF HEMATOLOGY期刊下所有文献 > Percentages of bone marrow blasts and chromosomal changes in patients with refractory anemia help to determine prognoses.

Percentages of bone marrow blasts and chromosomal changes in patients with refractory anemia help to determine prognoses.

Abstract：

:We statistically analyzed the hematologic findings of patients with refractory anemia (RA) to identify parameters associated with a poor prognosis. We first separated the RA patients into two groups: one group with disease progression and one without. The patients with disease progression were predominantly male and had a significantly higher percentage of bone marrow (BM) blasts at the time of diagnosis (3.06 +/- 1.29% vs. 1.44 +/- 1.38%, P < 0.005). This finding was confirmed when the patients were separated into the two groups; those who survived and those who expired (BM blasts: 2.68 +/- 1.59% vs. 1.37 +/- 1.27%, P < 0.005). The survival probabilities were calculated depending on whether or not the RA patients had > or = 3% BM blasts. The RA patients with > or = 3% BM blasts had a significantly worse prognosis (P < 0.01) than the patients with < 3% BM blasts. Notably, the RA patients with > or = 3% BM blasts did not show any significant differences in the incidence of disease progression, mortality rate, or survival probability, when compared with the patients with RA with an excess of blasts (RAEB). The present findings indicate that RA patients are heterogeneous with regard to prognosis, and the RA patients with > or = 3% BM blasts might have a poorer prognosis than those with fewer BM blasts. Thus we propose a general approach in predicting the prognosis of RA patients: those with complex chromosomal changes will expire shortly. Secondly, when the patients do not have any complex changes, the prognosis might be linked to the percentage of BM-blasts at the MDS diagnosis.

journal_name

Int J Hematol

journal_title

International journal of hematology

authors

Iwabuchi A,Ohyashiki K,Ohyashiki JH,Kimura Y,Lin KY,Aizawa S,Nehashi Y,Miyazawa K,Yaguchi M,Toyama K

subject

Has Abstract

pub_date

1994-10-01 00:00:00

pages

207-13

issue

3

eissn

0925-5710

issn

1865-3774

journal_volume

60

pub_type

杂志文章

相关文献

INTERNATIONAL JOURNAL OF HEMATOLOGY文献大全
  • Exogenously expressed granulocyte colony-stimulating factor (G-CSF) receptor on K562 cells can transduce G-CSF-triggered growth and differentiation signals.

    abstract：:Human granulocyte colony-stimulating factor (G-CSF) receptor cDNA was introduced into the erythroleukemic cell line K562, which normally does not express the receptor, using lipofection transfection of a G-CSF receptor expression plasmid vector. Transfected cells expressed the receptor with a dissociation constant of ...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1016/0925-5710(95)00352-s

    authors： el-Sonbaty SS,Watanabe M,Hochito K,Yamaguchi K,Matsuda I,Tsuchiya H

    更新日期：1995-02-01 00:00:00

  • Severe bleeding tendency caused by leukemic infiltration and destruction of vascular walls in chronic neutrophilic leukemia.

    abstract：:Bleeding is reportedly one of the major causes of death in patients with chronic neutrophilic leukemia (CNL), but thrombocytopenia, abnormal platelet functions, or coagulopathy has been confirmed to be the cause of the bleeding tendency in only a small proportion of the patients. We report the case of a 49-year-old wo...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/BF02982088

    authors： Noguchi T,Ikeda K,Yamamoto K,Ashiba A,Yoshida J,Munemasa M,Takenaka K,Shinagawa K,Ishimaru F,Yoshino T,Niiya K,Harada M

    更新日期：2001-12-01 00:00:00

  • Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.

    abstract：:We present a patient with refractory multiple myeloma who showed a good response to a combination therapy with oral melphalan, dexamethasone, and thalidomide (MDT). A 48-year-old woman with myeloma refractory to thalidomide, dexamethasone, and clarithromycin received 6 mg melphalan for 4 days every 6 weeks in combinat...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1532/IJH97.06164

    authors： Asou N,Izuno Y,Okubo T,Ide K,Ueno H,Kawakita M,Mitsuya H,Hata H

    更新日期：2007-07-01 00:00:00

  • Increased frequency of monoclonal gammopathy of undetermined significance in patients with nonimmune chronic idiopathic neutropenia syndrome.

    abstract：:This study describes the frequency of monoclonal gammopathy of undetermined significance (MGUS) and the changes in some inflammation-related serum proteins in 157 patients with nonimmune chronic idiopathic neutropenia syndrome (NI-CINS). Of these patients, 42 had pronounced neutropenia with neutrophil counts < 1500/mi...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/BF02981959

    authors： Papadaki HA,Eliopoulos DG,Ponticoglou C,Eliopoulos GD

    更新日期：2001-04-01 00:00:00

  • Ph1-positive acute lymphoblastic leukemia associated with an isochromosome 17q.

    abstract：:We report a patient with Ph1-positive acute lymphoblastic leukemia (ALL) having i(17q) in whom bony lesions were the initial clinical manifestation. The patient was a 53-year-old male who began to have pains in his left hip early in March 1985. Relevant findings on admission included: WBC 21,300/microliters; blast cel...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：

    authors： Kageyama T,Takiuchi H,Hasegawa M,Ohyabu H,Horiike S

    更新日期：1991-06-01 00:00:00

  • Allogeneic bone marrow transplantation of chronic myeloid leukemia from an HLA-matched unrelated donor with the beta-thalassemic trait.

    abstract：:We report a chronic myeloid leukemia patient who underwent allogeneic bone marrow transplantation from an HLA-matched unrelated donor with the beta-thalassemic trait. The donor was a heterozygote for the -28 A-->G mutation. We examined the recipient's bone marrow and peripheral blood using the polymerase chain reactio...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：

    authors： Sue YC,Liu TC,Chang CS,Huang SM,Chen TP,Lin SF

    更新日期：1999-04-01 00:00:00

  • Impaired fibrinolytic capacity in rheumatic mitral stenosis with or without atrial fibrillation and nonrheumatic atrial fibrillation.

    abstract：:Chronic atrial fibrillation (AF) has often been associated with systemic embolization, and patients with mitral stenosis (MS) have the highest thromboembolic risk. Increased risk of thromboembolism could be in part due to impaired fibrinolytic function. Global fibrinolytic capacity (GFC) is an innovative technique for...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/BF02982584

    authors： Atalar E,Ozmen F,Haznedaroğlu I,Ozer N,Aksöyek S,Ovünç K,Nazli N,Kirazli S,Kes S

    更新日期：2002-08-01 00:00:00

  • Splenectomy for severe autoimmune cytopenias after allogenic stem cell transplantation: case report.

    abstract：:Autoimmune cytopenias are rare but serious complications after hematopoietic stem cell transplantation (HSCT). We per-formed splenectomy in 2 patients who had severe autoimmune cytopenias after allogeneic HSCT (allo-HSCT) that were resist-ant to immunosuppressive treatment. The first patient underwent unrelated allo-H...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1532/ijh97.e0430

    authors： Proleznik I,Prentice HG,Pretnar J,Zver S,Cernelc P

    更新日期：2005-07-01 00:00:00

  • Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.

    abstract：:The wild-type Wilms tumor gene, WT1, is overexpressed in myelodysplastic syndrome (MDS) as well as acute myeloid leukemia. In a phase I clinical trial of biweekly vaccination with HLA-A*2402-restricted WT1 peptide for these malignancies, 2 patients with MDS developed severe leukocytopenia in association with a reducti...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1532/IJH97.06194

    authors： Kawakami M,Oka Y,Tsuboi A,Harada Y,Elisseeva OA,Furukawa Y,Tsukaguchi M,Shirakata T,Nishida S,Nakajima H,Morita S,Sakamoto J,Kawase I,Oji Y,Sugiyama H

    更新日期：2007-06-01 00:00:00

  • Neutrophil cytoskeletal disease.

    abstract：:Neutrophils and other phagocytes migrate to the site of infection, ingest pathogens, and destroy them after releasing granule contents and active oxygen. These activities of the cells are closely associated with a rapid reorganization of the cytoskeleton, in which actin polymerizes, cross-links, anchors to the membran...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/BF02981993

    authors： Nunoi H,Yamazaki T,Kanegasaki S

    更新日期：2001-08-01 00:00:00

  • Signal transduction in macrophages: negative regulation for macrophage colony-stimulating factor receptor signaling.

    abstract：:The receptor for macrophage colony-stimulating factor (M-CSF) is expressed in monocytes/macrophages and their progenitor cells and stimulates both the growth and development of the blood-cell lineage. Although the specific components positively regulating M-CSF receptor signaling have been relatively well defined, it ...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/BF02982712

    authors： Suzu S,Motoyoshi K

    更新日期：2002-07-01 00:00:00

  • Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.

    abstract：:A phase 1/2 study was conducted to assess the safety and efficacy of dasatinib in Japanese patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) resistant or intolerant to imatinib. In phase 1, 18 patients with chronic phase (CP) CML were treated ...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-009-0260-2

    authors： Sakamaki H,Ishizawa KI,Taniwaki M,Fujisawa S,Morishima Y,Tobinai K,Okada M,Ando K,Usui N,Miyawaki S,Utsunomiya A,Uoshima N,Nagai T,Naoe T,Motoji T,Jinnai I,Tanimoto M,Miyazaki Y,Ohnishi K,Iida S,Okamoto S,Seriu

    更新日期：2009-04-01 00:00:00

  • Bone marrow transplantation with a reduced-intensity conditioning regimen in a patient with Wegener granulomatosis and therapy-related leukemia.

    abstract：:We describe a patient with Wegener granulomatosis (WG) who underwent long-term cyclophosphamide treatment and thereafter developed acute myelogenous leukemia (AML). After the AML was induced into remission, the patient received an allogeneic stem cell transplant (allo-SCT) from his sibling after undergoing a reduced-i...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1532/IJH97.05148

    authors： Kunitomi A,Ishikawa T,Tajima K,Konaka Y,Yagita M

    更新日期：2006-04-01 00:00:00

  • Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.

    abstract：:The paradox of myelodysplastic syndromes (MDS) which present with pancytopenias despite cellular bone marrows (BM) was investigated by conducting detailed studies of proliferation and apoptosis in 89 MDS patients. Our results demonstrated a rapid rate of both proliferation as well as apoptosis. Levels of three cytokin...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1016/0925-5710(96)00455-0

    authors： Raza A,Mundle S,Shetty V,Alvi S,Chopra H,Span L,Parcharidou A,Dar S,Venugopal P,Borok R,Gezer S,Showel J,Loew J,Robin E,Rifkin S,Alston D,Hernandez B,Shah R,Kaizer H,Gregory S

    更新日期：1996-06-01 00:00:00

  • Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical h

    abstract：:Bortezomib is a proteasome inhibitor that can be effective in the treatment of refractory and relapsed multiple myeloma. Recently, severe pulmonary complications associated with bortezomib therapy have been reported in Japan. Because bortezomib has not yet been approved for general use in Japan and is imported by atte...

    journal_title：International journal of hematology

    pub_type： 杂志文章,多中心研究

    doi：10.1532/IJH97.06142

    authors： Gotoh A,Ohyashiki K,Oshimi K,Usui N,Hotta T,Dan K,Ikeda Y

    更新日期：2006-12-01 00:00:00

  • Molecular basis of clonal evolution in multiple myeloma.

    abstract：:The treatment outcome of multiple myeloma (MM) is worse than expected from the average numbers of non-synonymous mutations, which are roughly correlated with the prognosis of cancer patients. The refractoriness of MM may be ascribed to the complex genomic architecture and clonal behavior of the disease. In MM, disease...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/s12185-020-02829-6

    authors： Furukawa Y,Kikuchi J

    更新日期：2020-04-01 00:00:00

  • Successful engraftment of allogeneic peripheral blood stem cell transplant after nonmyeloablative preparative regimen with cytarabine and cyclophosphamide: report of 2 cases.

    abstract：:We report our experience with allogeneic peripheral blood stem cell transplantation (allo-PBSCT) following a nonmyeloablative conditioning regimen consisting of cytarabine (8 g/m2) and cyclophosphamide (120 mg/kg) in the treatment of 2 patients aged 50 and 55 years with refractory chronic myelomonocytic leukemia and c...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：

    authors： Fujii N,Maeda Y,Takenaka K,Shinagawa K,Imai T,Kozuka T,Ikeda K,Sunami K,Hiramatsu Y,Ishimaru F,Niiya K,Harada M

    更新日期：2000-12-01 00:00:00

  • The role of the AML1 transcription factor in leukemogenesis.

    abstract：:Chromosomal translocations are one of the hallmarks of human leukemias. These structural abnormalities result in the generation of genetic mutations that play a direct role in the transformation of hematopoietic stem cells. Some of the most common targets of these chromosomal rearrangements are the genes that encode t...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/BF02982058

    authors： Lorsbach RB,Downing JR

    更新日期：2001-10-01 00:00:00

  • Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?

    abstract：:Severe hyperlipidaemia with asparaginase therapy is rare. We report six cases, four of which developed significant problems with severe hyperlipidaemia during induction therapy for ALL and lymphoblastic lymphoma. The median triglyceride level was 22.3 mmol/L and the median cholesterol level was 12.3 mmol/L. None of th...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-011-0966-9

    authors： Lashkari HP,Lancaster D,Atra A,Champion MP,Taj MM

    更新日期：2011-12-01 00:00:00

  • Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors.

    abstract：:Chronic lymphocytic leukemia (CLL) shows a remarkable heterogeneity, with some patients having an almost normal lifespan, others surviving only several months after diagnosis despite intensive therapy. The aim of this study was to investigate the serum thymidine kinase 1 (TK1) concentration in Chinese patients with CL...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-009-0380-8

    authors： Xu W,Cao X,Miao KR,Qiao C,Wu YJ,Liu Q,Fan L,Li JY

    更新日期：2009-09-01 00:00:00

  • Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.

    abstract：:Elderly/comorbid patients with chronic lymphocytic leukemia (CLL) require low-toxicity treatments. Internationally, the standard treatment for such patients is chlorambucil and an anti-CD20 therapy; however, chlorambucil is not approved in Japan. The aim of the present study was to evaluate the safety, efficacy and ph...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-017-2233-1

    authors： Hatake K,Ogura M,Takada K,Taniwaki M,Zhang F,Fujita T,Ando K

    更新日期：2017-08-01 00:00:00

  • International collaboration on childhood leukemia.

    abstract：:The current cure rate of childhood acute lymphoblastic leukemia has reached 80% in many industrialized countries, but in developing countries the rate is often less than 10%. To advance the cure rate, investigators have formed several parallel initiatives in both industrialized and developing countries through interna...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/BF02983810

    authors： Pui CH,Ribeiro RC

    更新日期：2003-12-01 00:00:00

  • Two cases showing clonal progression with full evolution from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome to myelodysplastic syndromes and leukemia.

    abstract：:We report 2 paroxysmal nocturnal hemoglobinuria (PNH) patients who were initially diagnosed with aplastic anemia and sequentially developed PNH, myelodysplastic syndromes (MDS), and leukemia. Flow cytometry and cytogenetic analysis showed the initial appearance and expansion of PNH clones, gradual replacement of PNH c...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：

    authors： Ishihara S,Nakakuma H,Kawaguchi T,Nagakura S,Horikawa K,Hidaka M,Asou N,Mitsuya H

    更新日期：2000-08-01 00:00:00

  • Multiple myeloma presenting as bilateral breast lumps in pregnant woman.

    abstract：BACKGROUND:Multiple myeloma (MM) is a systemic disease in the elderly. Its incidence in patients younger than 40 years old and especially in pregnant women is extremely rare. MM may involve extraosseous sites, and only in rare cases it is observed in the breast. CASE REPORT:We describe the case of a 39-year-old woman ...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-013-1420-y

    authors： Bouzguenda R,Khanfir A,Toumi N,Chaaben K,Hentati Y,Ayadi L,Feki W,Daoud J,Frikha M

    更新日期：2013-10-01 00:00:00

  • Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

    abstract：:Previous studies have suggested that an increase in mitochondrial reactive oxygen species may cause organ damage in patients with light-chain (AL) amyloidosis; however, this damage can be decreased by antioxidant-agent treatment. Epigallocatechin gallate (EGCG), the major natural catechin in green tea, has potent anti...

    journal_title：International journal of hematology

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s12185-016-2112-1

    authors： Meshitsuka S,Shingaki S,Hotta M,Goto M,Kobayashi M,Ukawa Y,Sagesaka YM,Wada Y,Nojima M,Suzuki K

    更新日期：2017-03-01 00:00:00

  • Iron metabolism in erythroid cells and patients with congenital sideroblastic anemia.

    abstract：:Sideroblastic anemias are anemic disorders characterized by the presence of ring sideroblasts in a patient's bone marrow. These disorders are typically divided into two types, congenital or acquired sideroblastic anemia. Recently, several genes were reported as responsible for congenital sideroblastic anemia; however,...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/s12185-017-2368-0

    authors： Furuyama K,Kaneko K

    更新日期：2018-01-01 00:00:00

  • Persistent remission after immunosuppressive therapy of hairy cell leukemia mimicking aplastic anemia: two case reports.

    abstract：:Some patients with hairy cell leukemia (HCL) manifest pancytopenia and bone marrow hypoplasia without an apparent increase in atypical cells, so their disease resembles severe aplastic anemia at onset. We treated 2 HCL patients, who were initially diagnosed with aplastic anemia, with antithymocyte globulin (ATG) in co...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/BF02982650

    authors： Sugimori C,Kaito K,Nakao S

    更新日期：2003-05-01 00:00:00

  • Successful cord blood transplantation for mycosis fungoides.

    abstract：:A 26-year-old female diagnosed as mycosis fungoides (MF, clinical stage IV) was treated with single-agent chemotherapy, multi-drug chemotherapy and unrelated bone marrow transplantation with reduced-intensity conditioning (engraftment failure), resulting in failure. Unrelated cord blood transplantation (CBT) as second...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-008-0190-4

    authors： Fukushima T,Horio K,Matsuo E,Imanishi D,Yamasaki R,Tsushima H,Imaizumi Y,Ohshima K,Hata T,Yoshida S,Miyazaki Y,Tomonaga M

    更新日期：2008-12-01 00:00:00

  • Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood.

    abstract：:We have previously shown the clinical usefulness of Wilms' tumor 1 gene (WT1) mRNA expression in peripheral blood (PB) as a minimal residual disease (MRD) monitoring marker in 191 acute myeloid leukemia (AML) patients using the WT1 mRNA assay kit "Otsuka" (Otsuka Pharmaceutical Co., Ltd.; "former kit"). In contrast, t...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-015-1882-1

    authors： Kitamura K,Nishiyama T,Ishiyama K,Miyawaki S,Miyazaki K,Suzuki K,Masaie H,Okada M,Ogawa H,Imai K,Kiyoi H,Naoe T,Yokoyama Y,Chiba S,Hata T,Miyazaki Y,Hatta Y,Takeuchi J,Nannya Y,Kurokawa M,Ueda Y,Koga D,Sugiyam

    更新日期：2016-01-01 00:00:00

  • Clinical response of antilymphocyte globulin-based treatment in patients in taiwan with aplastic anemia: positive hepatitis C antibody may represent a response predictor.

    abstract：:Immunosuppression (IS) therapy with antilymphocyte globulin (ALG) is currently the treatment of choice for patients with aplastic anemia who do not have histocompatible sibling donors or who are not candidates for allogeneic bone marrow transplantation. Thirty-eight patients with aplastic anemia who received ALG-based...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1532/ijh97.a10306

    authors： Feng YH,Yen CJ,Huang WT,Su WC,Chen TY,Tsao CJ

    更新日期：2004-02-01 00:00:00